The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...

Viatris offers value with high free cash flow and dividends but faces growth challenges from legacy drug price erosion and ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

Viatris's phase 3 trial for pimecrolimus 0.3% in blepharitis failed to meet its primary endpoint of debris resolution after ...

Viatris is all set to release its fiscal second-quarter earnings next month, and analysts project a double-digit earnings drop.

Healthcare company Viatris has been certified as a Great Place to Work® in both Australia and New Zealand, marking the first ...

Shares of Viatris Inc. VTRS advanced 1.41% to $9.37 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.78% to 6,358.91 and ...

Pittsburgh, USA-based Viatris, which was formed in 2020 through the merger of Mylan and Pfizer's, saw its shares fall 4.2% to ...

Viatris reported that its MR-139 ophthalmic ointment failed to meet its primary endpoint in a Phase III blepharitis trial, while advancing its MR-141 and MR-142 candidates in presbyopia and night ...

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

Viatris announces phase 3 study of MR-139 for blepharitis fails to meet its primary endpoint: Pittsburgh Monday, July 21, 2025, 11:00 Hrs [IST] Viatris Inc., a global healthcare c ...